Clinical trials

18

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)

This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.

Participants needed: 10
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Apr 28, 2026Locations: 1
Eligibility criteria

Male adult patient who is at 18 years old or above, or female adult patient who... [+6]

Patient presenting with known class III/IV congestive heart failure according to... [+5]

Status: Recruiting

A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence

This research is being done to determine if producing sperm after an ultrashort period of abstinence (1 hour of abstinence) will be effective in improving the rates of embryos with normal chromosomes (structures that carry genetic information) during in vitro fertilization (IVF) treatment. The investigators hypothesize that a shorter period of abstinence is effective at improving rates of normal chromosomes among embryos.

Participants needed: 187
Trial details
Age: 18-42Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Apr 21, 2026Locations: 1
Eligibility criteria

Subjects are nonpregnant females ≥ 18 years and ≤ 42 years of age. [+4]

Subjects are utilizing donor oocytes, donor sperm, or gestational carrier. [+10]

Status: Recruiting

Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)

CMD can be inherited in an autosomal dominant or recessive trait. CMD may also be caused by de novo mutations. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for CMD. The investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The investigators long-term goal is to find mechanisms to slow down bone deposition in CMD patients.

Participants needed: 600
Trial details
Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Apr 17, 2026Locations: 1
Eligibility criteria

CMD; unaffected individuals only if part of a participating CMD family

No CMD; unaffected individuals only as part of a participating CMD family

Status: Recruiting

Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)

The goal of this research study is to identify genes and regulatory elements on chromosomes that cause ACC. The investigators also study tissue samples from patients to learn about the processes that lead to this disorder.

Participants needed: 600
Trial details
Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

ACC; unaffected individuals only if part of a participating ACC family

No ACC unaffected individuals only as part of a participating ACC family

Status: Recruiting

Genetic and Functional Analysis of Cherubism

The goal of this research study is to identify genes and regulatory elements on chromosomes that cause cherubism. Together with the investigators collaborators the investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The long-term goal of researchers involved in this study is to find mechanisms to slow down bone resorption in cherubism patients.

Participants needed: 600
Trial details
Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

cherubism; unaffected individuals only if part of a participating cherubism fami...

no cherubism unaffected individuals only as part of a participating cherubism fa...

Status: Recruiting

Genetic Analysis of Keloids

Keloids have a strong genetic component. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.

Participants needed: 7,000
Trial details
Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

keloids; [+1]

no keloids; [+1]

Status: Recruiting

Novel Approaches to the Treatment of Hypothyroidism

Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism. To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine/liothyronine combination therapy.

Participants needed: 90
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Mar 19, 2026Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

Partnering to Enhance Emerging Adults' Response to Programs

The goal of this clinical trial (CT) is to learn more about emerging adults' and their peers. Here, we will see how co-participating with a peer in health program might impact brain and behavior change over time. Eligible youth will be invited to come in for a "Participation Day," during which they and a peer will independently complete questionnaires. With a peer, they will then complete a short health program, and undergo a brain scan (fMRI) while completing activities. Our study team will reach out to each participant individually again 3, 6, and 12 months later to learn about health behaviors over time.

Participants needed: 248
Trial details
Age: 18-19Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Feb 10, 2026Locations: 1
Eligibility criteria

within the specified age range [+2]

left-handed [+3]

Status: Recruiting

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.

Participants needed: 60
Trial details
Phase: Phase 2Age: 65-80Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Jan 9, 2026Locations: 1
Eligibility criteria

men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/... [+1]

A vaccination in past two weeks [+13]

Status: Recruiting

Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.

Participants needed: 30
Trial details
Age: 50-80Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Sep 29, 2025Locations: 1
Eligibility criteria

Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100 [+5]

Beta blocker was prescribed for treating other cardiac conditions such as atrial... [+3]

Status: Not yet recruiting

Opioid Package Prototype (OPP)

The overall objective of this clinical trial is to identify the impact of selected package features, known as the Opioid Package Prototype (OPP), on the safe and effective use of opioids. Our specific aims are: (Aim 1) to evaluate the effectiveness of OPP on prescribing, dispensing, and patient use of oxycodone among orthopaedic surgery patients receiving post-operative outpatient oxycodone for post-surgical pain management, and (Aim 2) to determine the feasibility of OPP for orthopaedic surgery prescribers, pharmacists, and orthopaedic surgery patients. Such data can be used to further optimize packaging and labeling design, help patients and caregivers utilize their medication and packaging correctly, and improve prescribing and dispensing habits. The central hypothesis is that the OPP will be more effective than the amber vial in efforts to reduce oxycodone prescribing among patients over 18 receiving short-term management of post orthopedic surgery pain.

Participants needed: 352
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Sep 5, 2025Locations: 1
Eligibility criteria

The patient is 18 years and older; [+7]

Status: Recruiting

Study of Circulating Monocytes in Patients With Ischemic Vascular Disease

The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called "P2X4" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries. The researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Aug 14, 2025Locations: 1
Eligibility criteria

STEMI Patients: Men and women aged 18 years and over, with symptoms, physical si... [+4]

Subjects who are unable to give informed consent (with the exception of the isch... [+1]

Status: Recruiting

Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Aug 12, 2025Locations: 1
Eligibility criteria

Individuals aged >18yrs [+4]

Subjects who are unable to give informed consent [+2]

Status: Recruiting

Circulating Markers for Ischemic Heart Disease

The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.

Participants needed: 550
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UConn HealthUpdated: Aug 12, 2025Locations: 1
Eligibility criteria

men and women, 18 years of age and over with acute myocardial infarction (determ... [+2]

Subjects unable to give consent [+1]

Status: Recruiting

Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait

This is a cross-sectional, clinical research study comparing postmenopausal women of African Descent (AD) with different hemoglobin genotypes: normal and sickle cell trait (SCT). This research study has two purposes. The first purpose is to determine whether having SCT is a risk factor for the development of bone thinning in older women. The second purpose is to investigate whether women with SCT have reduced muscle function and increased frailty compared to women without SCT. The investigators estimate enrolling 50 female volunteers who are at least 50 years old and have not had a menstrual period for at least 12 consecutive months. Volunteers need not know whether they have SCT as this will be evaluated as part of the study.

Participants needed: 50
Trial details
Age: 50+Biological sex: FemaleType: ObservationalSponsor: UConn HealthUpdated: Jul 24, 2025Locations: 1
Eligibility criteria

Female of African Decent. [+2]

Taking medications known to influence bone metabolism (e.g., glucocorticoids, ho... [+3]

Status: Recruiting

Managing Anxiety in Pediatric Primary Care (MAPP)

The goal of this clinical trial is to conduct a randomized controlled trial to enhance the capacity of pediatric primary care providers to assist their patients who struggle with anxiety. The study aims to refine and assess the feasibility of the Anxiety Action Plan (AxAP), a brief intervention to reduce pediatric anxiety, delivered by primary care providers (PCPs) in community pediatric primary care clinics. The goal of the AxAP is to enhance the capacity of PCPs to identify and intervene with anxious youth, which will enhance access to care in general and especially in locations with few mental health specialists. PCPs participating in this study will attend a training, administer the intervention to enrolled youth assigned to the MAPP condition, participate in coaching sessions, and fill out study questionnaires. Families participating in this study will complete evaluations with the study team, receive the intervention from their PCP (if assigned to the MAPP condition), and fill out study questionnaires. Researchers will compare the MAPP intervention to Enhanced Usual Care (EUC; consisting of videos, handouts, and other resources for anxiety reduction) to see the differences, if any, in child outcomes.

Participants needed: 60
Trial details
Age: 6-17Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Dec 9, 2024Locations: 1
Eligibility criteria

6-17 years of age [+1]

Have a medical or psychiatric condition contraindicating participation (e.g., su... [+2]

Status: Recruiting

Efficacy Trial of the CALM Intervention

Excessive anxiety among elementary students is highly prevalent and associated with impairment in academic, social, and behavioral functioning. The primary aim of this project is to evaluate the initial efficacy of a brief nurse-delivered intervention (CALM: Child Anxiety Learning Modules), relative to a credible comparison (CALM-R, relaxation skills only) and a waitlist control for reducing anxiety symptoms and improving education outcomes at post intervention and at a 1-year follow-up. In addition, the research team will assess the cost effectiveness of CALM versus CALM-R and the waitlist control and examine potential predictors, moderators, and mediators of CALM's impact on child outcomes based on the proposed theory of change.

Participants needed: 218
Trial details
Age: 5-12Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Dec 9, 2024Locations: 2
Eligibility criteria

Be between the ages of 5-12 [+3]

Children who do not meet the inclusion criteria [+3]

Status: Recruiting

Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome

This study aims to examine the effect of force levels in orthodontic treatment during canine retraction. Force levels refer to the pressure applied by the orthodontic devices to move teeth. Data collection will include gingival fluid, dental molds from a digital scanner, and x-rays of the upper canine region on both sides of the mouth during treatment. The null hypothesis to be tested is that there is no significant difference in the rate of canine movement between the light force and the heavy force levels.

Participants needed: 40
Trial details
Age: 11-16Biological sex: AllType: InterventionalSponsor: UConn HealthUpdated: Nov 26, 2024Locations: 1
Eligibility criteria

Healthy patient, non-smoker [+6]

Patients under 11 years of age and over the age of 16. [+10]